Glaucoma News and Research

Latest Glaucoma News and Research

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

By 2020, nearly 80 million people are expected to have glaucoma, a disorder of the eye that, if left untreated, can damage the optic nerve and eventually lead to blindness.

19 Feb 2014

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, performed the first procedures using the ReSure Sealant on his cataract patients in Durham, North Carolina. The ReSure Sealant is the first FDA-approved sealant for ophthalmic use to seal incisions following cataract surgery.

18 Feb 2014

Dua's Layer in the human cornea may be linked to glaucoma

A new layer in the human cornea - discovered by researchers at The University of Nottingham last year - plays a vital role in the structure of the tissue that controls the flow of fluid from the eye, research has shown.

17 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma.

24 Jan 2014

Clues of "silent thief of sight”: Glaucoma

Glaucoma is sometimes called the "silent thief of sight" because it slowly damages the eyes and can cause irreparable harm before there is any vision loss. But this disease is stealthy in more ways than one.

22 Jan 2014

Probability of blindness from glaucoma drops by half, say researchers

A comparative long-range study by Mayo Clinic ophthalmology researchers shows that the probability of blindness from glaucoma 20 years after diagnosis has dropped by half in the last generation. The findings appear online in the "in press" section of the journal Ophthalmology.

22 Jan 2014

Study: Probability of blindness due to glaucoma has decreased by nearly half

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.

21 Jan 2014

Sleeping position influences glaucoma visual loss

Researchers from South Korea suggest that patients with glaucoma should avoid sleeping on one side, after showing that it may be associated with greater visual field loss in the lower-positioned eye.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

10 Jan 2014

Akorn acquires NDA and all rights to Betimol from Santen

Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Residual structures in brain play key role in restoring vision in stroke patients

Scientists know that vision restoration training (VRT) can help patients who have lost part of their vision due to glaucoma, optic nerve damage, or stroke regain some of their lost visual functions, but they do not understand what factors determine how much visual recovery is achieved.

6 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Scientists develop new potential cure for rare eye disease

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

22 Dec 2013

New optical device puts the power to detect retinal disease in the palm of a hand

A new optical device puts the power to detect eye disease in the palm of a hand. The tool-about the size of a hand-held video camera-scans a patient's entire retina in seconds and could aid primary care physicians in the early detection of a host of retinal diseases including diabetic retinopathy, glaucoma and macular degeneration.

22 Dec 2013

Glaucoma News and Research

Latest Glaucoma News and Research

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Dua's Layer in the human cornea may be linked to glaucoma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida announces financial results for second quarter 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Clues of "silent thief of sight”: Glaucoma

Probability of blindness from glaucoma drops by half, say researchers

Study: Probability of blindness due to glaucoma has decreased by nearly half

Sleeping position influences glaucoma visual loss

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Akorn acquires NDA and all rights to Betimol from Santen

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Residual structures in brain play key role in restoring vision in stroke patients

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Scientists develop new potential cure for rare eye disease

New optical device puts the power to detect retinal disease in the palm of a hand

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in